Companies › Kardigan
3 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| danicamtiv Cardiac myosin activator | MYH7, MYH6, MYH7B, MYL3, MYL2 | Phase 3 | Symptomatic Genetic Dilated Cardiomyopathy (DCM); Symptomatic Genetic Dilated Cardiomyopathy | Sep 2027 |
| Tonlamarsen Antisense oligonucleotide targeting ALOX5AP; reduces leukotriene production to lower blood | ALOX5AP | Phase 2 | Hypertension | Dec 2026 |
| Ataciguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Moderate Aortic Valve Stenosis | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07511361 | Tonlamarsen | Phase 2 | Hypertension | Cardiovascular | Dec 2026 |
| NCT07210723 | danicamtiv | Phase 2 | Symptomatic Genetic Dilated Cardiomyopathy | Cardiovascular | Sep 2027 |
| NCT07001800 | Ataciguat | Phase 2 | Moderate Aortic Valve Stenosis | Cardiovascular | Aug 2028 |
| NCT07771465 | danicamtiv | Phase 3 | Symptomatic Genetic Dilated Cardiomyopathy (DCM) | Cardiovascular | Nov 2032 |
Cash and short-term investments of $661m on 2026-06-30; operating cash outflow about $218m a year; runway about 36 months at that burn, to Jul 2029; 3 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
ALOX5AP (1) GUCY1B1 (1) GUCY1A2 (1) GUCY1A1 (1) MYH7 (1) MYH6 (1) MYH7B (1) MYL3 (1) MYL2 (1)
Merck & Co. (MSD) Bayer Akebia Therapeutics Pulmovant Coherus Oncology Bristol-Myers Squibb Cytokinetics
Cytokinetics Tectonic Therapeutic Pulmovant Inhibikase Therapeutics Thryv Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.